The invention relates to methods, kits and compositions for reducing the level of or eliminating Bacteroides in situ. The invention encompasses methods of preventing myocarditis, treating myocarditis or dilated cardiomyopathy, or limiting progression of myocarditis toward dilated cardiomyopathy in a subject in need thereof, comprising reducing the amount of Bacteroides sp. in the subject. The invention further encompasses methods of diagnosis of a subject as having myocarditis or dilated cardiomyopathy. The invention also encompasses compositions preventing myocarditis, treating myocarditis or dilated cardiomyopathy, or limiting progression of myocarditis toward dilated cardiomyopathy in a subject in need thereof.

Provided herein are compositions and methods for the treatment or prevention of pathogenic infections.

Provided herein are compositions and methods for the treatment or prevention of pathogenic infections.

An “inverse” precipitation route to precipitate aqueous soluble species with copolymers as nanoparticles having a hydrophilic, polar core and a less polar shell is described.

An “inverse” precipitation route to precipitate aqueous soluble species with copolymers as nanoparticles having a hydrophilic, polar core and a less polar shell is described.

Provided herein are methods for making liposomal API formulations via continuous in-line diafiltration processes. Also provided herein are liposomal API formulations manufactured by the disclosed methods.

Provided herein are methods for making liposomal API formulations via continuous in-line diafiltration processes. Also provided herein are liposomal API formulations manufactured by the disclosed methods.

The present invention discloses glycopeptide compounds having activity of resisting drug-resistant bacteria, conforming to glycopeptide compounds represented by general formula (I), ##STR00001## The present invention also provides a preparation method for and an application of the glycopeptide compounds. Upon testing, compared with a second-generation glycopeptide drug oritavancin, the glycopeptide antibiotic compounds have higher inhibition activity on drug-resistant bacterial strains, especially MRSA or VRE. Further testing shows that most of the glycopeptide compounds have safety higher than that of oritavancin and can be prepared into drugs for treating or preventing diseases caused by various bacterial infections, such as skin and soft tissue infections, meningitis, sepsis, pneumonia, arthritis, peritonitis, bronchitis, and empyema.

The present invention discloses glycopeptide compounds having activity of resisting drug-resistant bacteria, conforming to glycopeptide compounds represented by general formula (I), ##STR00001## The present invention also provides a preparation method for and an application of the glycopeptide compounds. Upon testing, compared with a second-generation glycopeptide drug oritavancin, the glycopeptide antibiotic compounds have higher inhibition activity on drug-resistant bacterial strains, especially MRSA or VRE. Further testing shows that most of the glycopeptide compounds have safety higher than that of oritavancin and can be prepared into drugs for treating or preventing diseases caused by various bacterial infections, such as skin and soft tissue infections, meningitis, sepsis, pneumonia, arthritis, peritonitis, bronchitis, and empyema.

Methods of treating, reducing, or preventing lung infections or lung inflammation include identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Treatment of cystic fibrosis lung infections, COPD lung infections, inflammation of the lungs in these patient populations, and lung scarring in these patient populations is also described.